Surgery
Volume 145, Issue 5 , Pages 542-549 , May 2009

Pitavastatin prevents intestinal ischemia/reperfusion–induced bacterial translocation and lung injury in atherosclerotic rats with hypoadiponectinemia

,Accepted 8 January 2009.

References 

  1. Koike K, Moore FA, Moore EE, Read RA, Carl VS, Banerjee A. Gut ischemia mediates lung injury by a xanthine oxidase-dependent neutrophil mechanism. J Surg Res. 1993;54:469–473
  2. Collard CD, Gelman S. Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury. Anesthesiology. 2001;94:1133–1138
  3. Moore EE, Moore FA, Franciose RJ, Kim FJ, Biffl WL, Banerjee A. The postischemic gut serves as a priming bed for circulating neutrophils that provoke multiple organ failure. J Trauma. 1994;37:881–887
  4. Swank GM, Deitch EA. Role of the gut in multiple organ failure: bacterial translocation and permeability changes. World J Surg. 1996;20:411–417
  5. Turnage RH, Guice KS, Oldham KT. Pulmonary microvascular injury following intestinal reperfusion. New Horiz. 1994;2:463–475
  6. Martsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24:29–33
  7. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114:1752–1761
  8. Li R, Wang WQ, Zhang H, Yang X, Fan Q, Christopher TA, et al. Adiponectin improves endothelial function in hyperlipidemic rats by reducing oxidative/nitrative stress and differential regulation of eNOS/iNOS activity. Am J Physiol Endocrinol Metab. 2007;293:1703–1708
  9. Nakagawa H, Tsunooka N, Yamamoto Y, Yoshida M, Nakata T, Kawachi K. Intestinal ischemia/reperfusion-induced bacterial translocation and lung injury in atherosclerotic rats with hypoadiponectinemia. Surgery. 2009;145:48–56
  10. Blanco-Colio LM, Martín-Ventura JL, Gómez-Guerrero C, Masramon X, de Teresa E, Farsang C, et al. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. Eur J Pharmacol. 2008;586:259–265
  11. Joyce M, Kelly C, Winter D, Chen G, Leahy A, Bouchier-Hayes D. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion. J Surg Res. 2001;101:79–84
  12. Naidu BV, Woolley SM, Farivar AS, Thomas R, Fraga C, Mulligan MS. Simvastatin ameliorates injury in an experimental model of lung ischemia-reperfusion. J Thorac Cardiovasc Surg. 2003;126:482–489
  13. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, Lefer DJ. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation. 1999;100:178–184
  14. Samdani AF, Dawson TM, Dawson VL. Nitric oxide synthase in models of focal ischemia. Stroke. 1997;28:1283–1288
  15. Pirat A, Zeyneloglu P, Aldemir D, Ÿucel M, Ozen O, Candan S, et al. Pretreatment with simvastatin reduces lung injury related to intestinal ischemia-reperfusion in rats. Anesth Analg. 2006;102:225–232
  16. Chiu CJ, McArdle AH, Brown R, Scott HJ, Gurd FN. Intestinal mucosal lesion in low-flow states. Arch Surg. 1970;101:478–483
  17. Wattanasirichaigoon S, Menconi MJ, Delude RL, Fink MP. Effect of mesenteric ischemia and reperfusion or hemorrhagic shock on intestinal mucosal permeability and ATP content in rats. Shock. 1999;12:127–133
  18. Liu KX, Wu WK, He W, Liu CL. Ginkgo biloba extract (EGb 761) attenuates lung injury induced by intestinal ischemia/reperfusion in rats: roles of oxidative stress and nitric oxide. World J Gastroenterol. 2007;13:299–305
  19. Mallick IH, Yang W, Winsler MC, Seifalian AM. Ischemia-reperfusion injury of the intestine and protective strategies against injury. Dig Dis Sci. 2004;49:1359–1377
  20. Suzuki Y, Deitch EA, Mishima S, Lu Q, Xu D. Inducible nitric oxide synthase gene knockout mice have increased resistance to gut injury and bacterial translocation after an intestinal ischemia-reperfusion injury. Crit Care Med. 2000;28:3692–3696
  21. Virlos IT, Inglott FS, Williamson RC, Mathie RT. Differential expression of pulmonary nitric oxide synthase isoforms after intestinal ischemia-reperfusion. Hepatogastroenterology. 2003;50:31–36
  22. Turnage RH, Wright JK, Iglesias J, LaNoue JL, Nguyen H, Kim L, et al. Intestinal reperfusion-induced pulmonary edema is related to increased pulmonary inducible nitric oxide synthase activity. Surgery. 1998;124:457–463
  23. Kubes P, McCafferty DM. Nitric oxide and intestinal inflammation. Am J Med. 2000;109:150–158
  24. Nadler EP, Ford HR. Regulation of bacterial translocation by nitric oxide. Pediatr Surg Int. 2000;16:165–168
  25. Nishihara T, Matsuda M, Araki H, Oshima K, Kihara S, Funahashi T, et al. Effect of adiponectin on murine colitis induced by dextran sulfate sodium. Gastroenterology. 2006;131:853–861
  26. Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves reduction of oxidative/nitrative stress. Circulation. 2007;115:1408–1416
  27. Noji Y, Higashikata T, Inazu A, Nohara A, Ueda K, Miyamoto S, et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2002;163:157–164
  28. Saito Y, Yamada N, Teramoto T, Itakura H, Hata Y, Nakaya N, et al. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison. Arzneimittelforschung. 2002;52:251–255
  29. Han J, Zhou X, Yokoyama T, Hajjar DP, Gotto AM, Nicholson AC. Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36. Circulation. 2004;109:790–796
  30. Han J, Parsons M, Zhou X, Nicholson AC, Gotto AM, Hajjar DP. Functional interplay between the macrophage scavenger receptor class B type I and pitavastatin (NK-104). Circulation. 2004;110:3472–3479
  31. Wang J, Tokoro T, Matsui K, Higa S, Kitajima I. Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells. Life Sci. 2005;76:2257–2268
  32. Kibayashi E, Urakaze M, Kobashi C, Kishida M, Takata M, Sato A, et al. Inhibitory effect of pitavastatin (NK-104) on the C-reactive-protein-induced interleukin-8 production in human aortic endothelial cells. Clin Sci (Lond). 2005;108:515–521
  33. Kawakami A, Tani M, Chiba T, Yui K, Shinozaki S, Nakajima K, et al. Pitavastatin inhibits remnant lipoprotein-induced macrophage foam cell formation through ApoB48 receptor-dependent mechanism. Arterioscler Thromb Vasc Biol. 2005;25:424–429
  34. Inami N, Nomura S, Shouzu A, Kimura Y, Takahashi N, Tanaka A, et al. Effects of pitavastatin on adiponectin in patients with hyperlipidemia. Pathophysiol Haemost Thromb. 2007;36:1–8
  35. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–126
  36. van der Woude CJ, Kleibeuker JH, Jansen PL, Moshage H. Chronic inflammation, apoptosis and (pre-)malignant lesions in the gastro-intestinal tract. Apoptosis. 2004;9:123–130
  37. Beebe DS, Kim S, Belani KG, Fryer J, Benedetti E, Moon S, et al. Endotoxemia during small bowel transplantation in pigs. Transplant Proc. 1995;27:593–594
  38. Mishima S, Xu D, Lu Q, Deitch EA. The relationship among nitric oxide production, bacterial translocation, and intestinal injury after endotoxin challenge in vivo. J Trauma. 1998;44:175–182
  39. Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci. 2004;75:639–653
  40. Cross RK, Wilson KT. Nitric oxide in inflammatory bowel disease. Inflamm Bowel Dis. 2003;9:179–189
  41. Kobayashi T, Tani T, Yokota T, Kodama M. Detection of peptidoglycan in human plasma using the silkworm larvae plasma test. FEMS Immunol Med Microbiol. 2000;28:49–53

PII: S0039-6060(09)00027-0

doi: 10.1016/j.surg.2009.01.002

Surgery
Volume 145, Issue 5 , Pages 542-549 , May 2009

Article Tools

* Image Usage & Resolution